Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.35M | 2.22M | 1.83M | 1.54M | 1.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 800.00 | 800.00 | 800.00 | -186.40K | -- |
| Total Operating Expenses | 22.21M | 13.49M | 9.78M | 6.14M | 3.77M |
| Operating Income | -22.21M | -13.49M | -9.78M | -6.14M | -3.77M |
| Income Before Tax | -19.70M | -14.24M | -8.78M | -6.38M | -2.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.70 | -14.24 | -8.78 | -6.38 | -2.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.70M | -14.24M | -8.78M | -6.38M | -2.42M |
| EBIT | -22.21M | -13.49M | -9.78M | -6.14M | -3.77M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.43 | -1.94 | -1.23 | -0.95 | -0.38 |
| Normalized Basic EPS | -1.52 | -1.21 | -0.77 | -0.59 | -0.23 |
| EPS Diluted | -2.43 | -1.94 | -1.24 | -0.95 | -0.38 |
| Normalized Diluted EPS | -1.52 | -1.21 | -0.77 | -0.59 | -0.23 |
| Average Basic Shares Outstanding | 31.67M | 29.12M | 27.52M | 24.76M | 22.14M |
| Average Diluted Shares Outstanding | 31.67M | 29.12M | 28.00M | 25.24M | 22.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |